Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on
coagulation parameters, including a calibrated thrombin time test, in patients with moderate
renal impairment undergoing elective total hip- or knee-replacement surgery, this PK/PD study
will be conducted.